Roche Palo Alto LLC

Syntex (u.s.a.) Inc.

F. Hoffmann-la Roche Ag

Palo Alto LLC

Ro&cacute;he Palo Alto LLC

Counde O'Yang

Francisco Javier Lopez-Tapia

Alexander Victor Muehldorf

Alam Jahangir

Paul Francis Keitz

Robin D Clark

David Garrett Loughhead

Richard Leo Cournoyer

Thomas Weitao Sun

Dennis Mitsugu Yasuda

Bruce Andrew Kowalczyk

Keith Roger Bley

Michael Soth

Michael Patrick Dillon

Clara Jeou Jen Lin

Dov Nitzan

Lee Edwin Lowrie, Jr

Xiaoming Zhang

David Michael Goldstein

Roland Joseph Billedeau

Nolan James Dewdney

Leyi Gong

Tobias Gabriel

Nidhi Arora

David George Putman

Yun-chou Tan

Sanja Novakovic

Arthur F Kluge

Zachary Kevin Sweeney

Mark Smith

Keith Adrian Walker

Jim W Li

Robert J Greenhouse

Ryan Craig Schoenfeld

Shu-Hai Zhao

Todd Richard Elworthy

Terrence Joseph Connolly

Joan Heather Hogg

Daniel Lee Severance

Klaus K Weinhardt

Chris Richard Melville

Helen Y Wu

Amy Geraldine Moore

Teresa Alejandra Trejo-Martin

Joshua Kennedy-Smith

Joe Timothy Bamberg

Eun Kyung Lee

Meng Sui

Yansheng Zhai

Fernando Padilla

Walter Kurz

Jeffrey Wu

Patrick Finbar McGarry

Xao-Fa Lin

Anthony L Willis

Robert Greenhouse

Xiao-Fa Lin

Compounds of formula I, wherein R, R, R, X and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. 

Non-nucleoside reverse transcriptase inhibitors

The present invention relates to propionamide compounds of formula I for use as antiinflammatory agents: wherein R, Rand Rare as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to methods of using the compounds of formula I and pharmaceutical compositions comprising the compounds of formula I.

Propionamide compounds as antiinflammatory agents

This invention relates to an alpha-1 A receptor partial agonist, which is represented by Formula I: and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing formula I, methods for their use as therapeutic agents, and methods of preparation thereof.

Imidazolinylmethyl aryl sulfonamide

Compounds of formula I or formula II: or pharmaceutically acceptable salts thereof, wherein m, n, p, Ar R, R, R, and Rare as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds.

Indole and benzofuran 2-carboxamide derivatives and uses thereof

Compounds effective as p38 MAP kinase inhibitors, methods of making the compounds, and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.

Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors

Compounds of the formula Ia or Ib: wherein A, B, X, Y, Z, W, k, R, R, R, Rand Rare those defined herein, and compositions comprising the same. The present invention also provides methods for preparing compounds of formula I and using the same in treating p38 mediated disorders in a subject.

Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same

This invention relates to a method for modulating &#x3b1;subtype GABAreceptors with heterocyclic compounds of formula I, and salts, solvates and prodrugs thereof. The invention further relates to novel heteocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain 

[object Object]

Compounds of the formula (I): and pharmaceutically acceptable salts or prodrugs thereof, wherein X, Y, Z and Rare as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.

Pyrazolyl and imidazolyl pyrimidines as CRF antagonists

Compounds of the Formula: where R-Rare those defined herein and methods for producing the same. Also provided are pharmaceutical compositions comprising a Compound of Formula I and methods for their use as therapeutic agents.

Imidazolinylmethyl aralkylsulfonamides

This invention relates to a method for modulating &#x3b1;subtype GABAreceptors with heterocyclic compounds of formula I, and salts, solvates and prodrugs thereof. The invention further relates to said heterocyclic compounds and pharmaceutical compositions containing said compounds. In addition the invention relates to the treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder or pain 

Heterocyclic GABAA subtype selective receptor modulators

The present invention relates to compounds of formula I: wherein A, X, R, Rand Rare as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to methods of using the compounds of formula I and pharmaceutical compositions comprising the compounds of formula I.

Glucocorticoid receptor modulators as antiinflammatory agents

This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I: wherein:

Carboxylic acid derivatives as IP antagonists

This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I wherein Xis (CH)or CO, n is 0 to 2 and R, R, Rand Rare as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents 

Heterocyclic derivatives as CRF antagonists

Compounds effective as IP receptor modulators, particularly IP receptor antagonists, that are of the formula I: wherein A, R, R, Rand Rare as defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. Also disclosed are pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.

Substituted aryl amides as IP antagonists

This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein Ar is optionally substituted aryl or heteroaryl, R-Rare as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts thereof. The invention further relates to processes for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods for their use as therapeutic agents.

Ring fused pyrazole derivatives as CRF antagonists

Growing community of inventors

Sunnyvale, CA, United States of America

Counde O'Yang